IGC Pharma, Inc. (formerly Globalization Capital, Inc.) is launching a rebranding initiative to better represent its strategic focus and vision for the future. On March 30th, 2023, the company will begin operating under its new name: IGC Pharma, Inc. (dba IGC). This exciting new development marks a major milestone in the company’s evolution, setting the stage for a dynamic new chapter in its history.
On March 31, 2023, our common stock will begin trading on the NYSE American under the same symbol IGC. Our CUSIP and EIN numbers will remain the same, allowing investors to continue to easily track and trade our stock. Don’t miss out on this exciting opportunity to invest in our company and join us on our journey to success.
IGC Pharma, Inc. is a developer of drug assets dedicated to treating diseases such as Alzheimer’s. At the forefront of their pioneering research is the natural, cannabis-based, patent-protected compound IGC-AD1, which is currently undergoing FDA trials for the treatment of agitation in Alzheimer’s.
Preclinical studies have shown that the APIs in IGC-AD1 have the potential to be effective in ameliorating a key protein responsible for Aβ plaques, a hallmark of Alzheimer’s. In addition to IGC-AD1, the company also markets Holief™, a wellness brand targeting women with PMS, menstrual cramps, and sleep disorders.
IGC Pharma, Inc. (dba IGC) is proud to announce their transformation into a leading developer and provider of THC-based drug assets with a name change to reflect their strategic focus. With the promising results of their investigational drug candidate, IGC-AD1, in FDA trials for treating agitation in Alzheimer’s patients, and their consumer products gaining traction in the market, the rebranding and renaming of the Company is a major milestone in their progress. This marks a new era of growth and success as they realize their strategic vision and continue to develop innovative drug delivery solutions.
About IGCPharma, Inc.
IGC Pharma, operating under the name IGC, is at the cutting-edge of cannabinoid-based treatments for a variety of diseases and conditions, including Alzheimer’s disease, period cramps (“dysmenorrhea”), premenstrual syndrome (“PMS”) and chronic pain.
IGC’s two investigational drugs, IGC-AD1 and TGR-63, have demonstrated the potential to suppress or ameliorate the key hallmarks of Alzheimer’s disease, such as plaques and tangles, in Alzheimer’s cell lines. IGC-AD1, a low-dose tetrahydrocannabinol (“THC”) based formulation, is currently undergoing a 146-person Phase 2 safety and efficacy clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681).
Complementing this, IGC also markets a wellness brand, Holief™, that specifically targets women experiencing premenstrual syndrome and menstrual cramps. Headquartered in Maryland, USA, IGC has also typically maintained an infrastructure segment in India.